The latest price target for NovaBay Pharmaceuticals (AMEX:NBY) was reported by Ladenburg Thalmann on August 11, 2023. The analyst firm set a price target for $3.80 expecting NBY to rise to within 12 months (a possible 76.74% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for NovaBay Pharmaceuticals (AMEX:NBY) was provided by Ladenburg Thalmann, and NovaBay Pharmaceuticals maintained their buy rating.

There is no last upgrade for NovaBay Pharmaceuticals

There is no last downgrade for NovaBay Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NovaBay Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NovaBay Pharmaceuticals was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.

While ratings are subjective and will change, the latest NovaBay Pharmaceuticals (NBY) rating was a maintained with a price target of $6.00 to $3.80. The current price NovaBay Pharmaceuticals (NBY) is trading at is $2.15, which is out of the analyst’s predicted range.